objective previously downregulation bronchodilator desensitization albuterol occurred NUMBER hours stopping regular treatment twice daily salmeterol study evaluated effects formoterol given twice daily regular basis methods randomized doubleblind crossover study NUMBER subjects stable asthma mean sd age NUMBER NUMBER years mean sd fev1 NUMBER NUMBER percent predicted receiving regular inhaled corticosteroid therapy received NUMBER week treatment formoterol dry powder NUMBER microg twice daily NUMBER pm formoterol NUMBER microg daily NUMBER pm identical placebo lymphocyte parameters curve inhaled albuterol NUMBER NUMBER microg evaluated NUMBER hours dose treatment period results significant differences mean values albuterol effects treatment regimens comparison maximal bronchodilator responses treatments mean sem change baseline revealed significant differences treatments fev1 NUMBER l NUMBER l placebo vs NUMBER l NUMBER l NUMBER microg daily formoterol vs NUMBER l NUMBER l NUMBER microg twice daily formoterol forced expiratory flow phase NUMBER NUMBER placebo vs NUMBER NUMBER NUMBER microg daily formoterol vs NUMBER NUMBER NUMBER microg twice daily formoterol formoterol significant effect mean lymphocyte density seven patients homozygous polymorphism density downregulated twice daily formoterol cases exhibited reduction maximal fev1 response albuterol conclusions results study showed patients taking inhaled corticosteroids overall regulation associated bronchodilator sensitivity inhaled albuterol unaltered NUMBER hours stopping regular treatment formoterol subset patients homozygous tendency downregulation desensitization studies subjects severe asthma required assess clinical relevance findings beta2 adrenoceptor placebo controlled double dummy mild moderate beta2 adrenoceptor dose response dose response mid expiratory fef25 NUMBER beta2 adrenoceptor gly NUMBER beta2 adrenoceptor beta2 adrenoceptor gly NUMBER NUMBER l sec l sec l sec l sec l sec l sec